Sangamo BioSciences Inc. (SGMO) Sets New 12-Month Low at $4.19
Sangamo BioSciences Inc. (NASDAQ:SGMO) shares hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $4.19 and last traded at $4.25, with a volume of 556,772 shares traded. The stock had previously closed at $4.40.
A number of brokerages have recently issued reports on SGMO. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Sangamo BioSciences in a research report on Friday, May 6th. Jefferies Group reaffirmed a “buy” rating on shares of Sangamo BioSciences in a research report on Friday, August 5th. Wells Fargo & Co. began coverage on shares of Sangamo BioSciences in a research report on Tuesday, May 3rd. They issued a “buy” rating on the stock. Cowen and Company reaffirmed a “buy” rating on shares of Sangamo BioSciences in a research report on Wednesday, August 10th. Finally, Janney Montgomery Scott downgraded shares of Sangamo BioSciences from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $15.00 to $8.00 in a research report on Thursday, August 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. Sangamo BioSciences has an average rating of “Buy” and an average price target of $15.58.
The company’s market cap is $291.65 million. The firm has a 50 day moving average of $5.40 and a 200-day moving average of $5.90.
Sangamo BioSciences (NASDAQ:SGMO) last announced its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.14. During the same period in the previous year, the business posted ($0.17) earnings per share. The business had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.38 million. Sangamo BioSciences’s revenue for the quarter was down 56.0% compared to the same quarter last year. On average, analysts expect that Sangamo BioSciences Inc. will post ($1.11) earnings per share for the current year.
A hedge fund recently raised its stake in Sangamo BioSciences stock. Schwab Charles Investment Management Inc. raised its stake in Sangamo BioSciences Inc. (NASDAQ:SGMO) by 25.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 254,000 shares of the biopharmaceutical company’s stock after buying an additional 52,171 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.36% of Sangamo BioSciences worth $2,320,000 as of its most recent SEC filing.
Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.